Evaxion Biotech ( (EVAX) ) has shared an announcement.
On March 26, 2025, Evaxion Biotech announced the filing of a prospectus supplement for the issuance and sale of up to $4.48 million in American Depositary Shares (ADSs) under its existing Capital on Demand Sales Agreement with JonesTrading. This move follows a previous agreement from October 2022, which allowed the company to offer up to $14.44 million in ADSs. The company is not obligated to sell any ADSs, and the offering will terminate according to the agreement’s terms. This strategic financial maneuver aims to bolster Evaxion’s capital resources, potentially enhancing its market position and operational capabilities in the biotech sector.
More about Evaxion Biotech
Evaxion Biotech A/S is a biotechnology company based in Denmark, focusing on developing AI-driven immunotherapies for cancer and infectious diseases. The company leverages its proprietary technology to design and develop novel treatments aimed at improving patient outcomes in these critical areas.
YTD Price Performance: -58.63%
Average Trading Volume: 2,461,966
Technical Sentiment Signal: Buy
Current Market Cap: $2.17M
For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.